James Vollins - 30 Apr 2023 Form 4 Insider Report for Eiger BioPharmaceuticals, Inc.

Role
General Counsel
Signature
/s/ James Vollins
Issuer symbol
N/A
Transactions as of
30 Apr 2023
Net transactions value
$0
Form type
4
Filing time
02 May 2023, 16:30:36 UTC
Previous filing
14 Apr 2023
SEC
View on sec.gov

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction EIGR Stock Option (Right to Buy) Award $0 +120,000 $0.000000 120,000 30 Apr 2023 Common Stock 120,000 $1.03 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The option vests as to twenty-five percent of the shares upon the one-year anniversary of April 12, 2023, and in 36 equal monthly installments thereafter, subject to Reporting Person's continuous service status as of each such date.